biospectrumasiaJune 04, 2018
Tag: Xynomic Pharma , Series B financing , oncology drug
Xynomic Pharma, a clinical stage US-China oncology drug development company, recently announced that it has completed Series B Crossover financing, led by experienced healthcare investors Northern Light Venture Capital, Zhongshan Bison Healthcare Investment Limited and Hakim Unique Internet Company Limited.
All existing investors including Prosperico Ventures and Mr. Yinglin Mark Xu, Xynomic Pharma's founder and Chairman, participated in this round of financing.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: